US Stock Insider Trading | CeriBell disclosed 1 insider transaction on February 23

K-LinePoet · 2026-02-24T22:23:32+00:00

On February 23, 2026, CeriBell disclosed the latest insider trading activity, with Director Parvizi Josef selling 16,700 shares on February 19, for a total of approximately $338,800. CeriBell is a medical technology company focused on the diagnosis and management of neurological diseases, developing an AI-based EEG platform to improve patient prognosis.

K-LinePoet

2026-02-24 22:23:32

Abstract generation in progress

On February 23, 2026, CeriBell (CBLL) disclosed one insider transaction. Director Parvizi Josef sold 16,700 shares on February 19, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Director	Parvizi Josef	February 19, 2026	Sell	16,700	20.27	338,800
February 19, 2026	Director	Parvizi Josef	February 18, 2026	Sell	8,286	20.00	165,700
February 6, 2026	Director	Chao Xingjuan	February 4, 2026	Buy	25,000	4.70	117,500
February 6, 2026	Director	Chao Xingjuan	February 4, 2026	Sell	39,000	20.16	786,200
February 5, 2026	Executive	Foehr David	February 3, 2026	Sell	5,556	20.00	111,100
February 5, 2026	Executive	Foehr David	February 3, 2026	Buy	5,556	4.70	26,100
February 4, 2026	Executive	Woo Raymond	February 2, 2026	Sell	4,497	20.57	92,500
February 4, 2026	Executive	Woo Raymond	February 2, 2026	Buy	9,640	4.70	45,300
February 4, 2026	Executive	Woo Raymond	February 2, 2026	Sell	6,615	20.54	135,900
February 4, 2026	Executive	Woo Raymond	February 2, 2026	Buy	1,472	2.24	3,297.28

[Company Profile]

CeriBell, Inc. was incorporated on August 29, 2014, in Delaware. They are a clinical-stage medical technology company focused on transforming the diagnosis and management of patients with severe neurological diseases. They developed the Ceribell system, a novel point-of-care EEG platform designed to meet unmet needs in acute care settings. The Ceribell system combines proprietary, highly portable, rapidly deployable hardware with complex AI-driven algorithms to enable rapid diagnosis and continuous monitoring of neurological conditions. By harnessing AI, the system makes EEG more accessible and allows for continuous monitoring, enabling clinicians to diagnose and manage patients at risk of seizures more quickly and accurately in acute care environments, thereby improving patient outcomes and economic benefits for hospitals and payers.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.